BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 16307000)

  • 1. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A canine minidystrophin is functional and therapeutic in mdx mice.
    Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
    Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
    Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
    Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins.
    Tidball JG; Wehling-Henricks M
    Mol Genet Metab; 2004 Aug; 82(4):312-20. PubMed ID: 15308129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
    Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
    Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
    Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
    Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex.
    Judge LM; Haraguchiln M; Chamberlain JS
    J Cell Sci; 2006 Apr; 119(Pt 8):1537-46. PubMed ID: 16569668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin and utrophin: genetic analyses of their role in skeletal muscle.
    Rafael JA; Brown SC
    Microsc Res Tech; 2000 Feb 1-15; 48(3-4):155-66. PubMed ID: 10679963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice.
    Chakkalakal JV; Harrison MA; Carbonetto S; Chin E; Michel RN; Jasmin BJ
    Hum Mol Genet; 2004 Feb; 13(4):379-88. PubMed ID: 14681302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.
    Rafael JA; Tinsley JM; Potter AC; Deconinck AE; Davies KE
    Nat Genet; 1998 May; 19(1):79-82. PubMed ID: 9590295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full-length dystrophin gene transfer to the mdx mouse in utero.
    Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
    Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.
    Sakamoto M; Yuasa K; Yoshimura M; Yokota T; Ikemoto T; Suzuki M; Dickson G; Miyagoe-Suzuki Y; Takeda S
    Biochem Biophys Res Commun; 2002 May; 293(4):1265-72. PubMed ID: 12054513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice.
    Wang B; Li J; Fu FH; Xiao X
    J Orthop Res; 2009 Apr; 27(4):421-6. PubMed ID: 18973234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
    Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin.
    Li S; Kimura E; Fall BM; Reyes M; Angello JC; Welikson R; Hauschka SD; Chamberlain JS
    Gene Ther; 2005 Jul; 12(14):1099-108. PubMed ID: 15759015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of full-length utrophin prevents muscular dystrophy in mdx mice.
    Tinsley J; Deconinck N; Fisher R; Kahn D; Phelps S; Gillis JM; Davies K
    Nat Med; 1998 Dec; 4(12):1441-4. PubMed ID: 9846586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.